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ABSTRACT 
 
RICHARD WYSS: Using High Dimensional Disease Risk Scores in Comparative Effectiveness 
Research of New Treatments 
(Under the direction of Dr. Til Stürmer) 
 
 Nonexperimental research using automated healthcare databases can supplement 
randomized trials to provide both clinicians and patients with timely information to optimize 
treatment decisions. These studies, however, are susceptible to confounding and require design 
and statistical methods to control for large numbers of confounding variables. The propensity 
score (PS), defined as the conditional probability of treatment given a set of covariates, has 
become increasingly popular for controlling large numbers of covariates in 
pharmacoepidemiologic studies. During early periods after the introduction of a new 
treatment, however, accurately modeling the PS can be difficult because of rapid change over 
time in drug prescribing patterns and few exposed individuals. A historically estimated disease 
risk score (DRS), which summarizes covariate associations with the outcome absent of 
exposure, has been proposed as an alternative to PSs for controlling large numbers of 
covariates during these periods. Little is known about the performance and potential benefits 
of using DRSs for confounding control when evaluating the comparative effectiveness of newly 
marketed drugs.  
In this study, we examined the benefits and challenges of using historically estimated 
DRSs compared to PSs when controlling for large numbers of covariates during early periods of 
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drug approval. We further evaluated novel strategies for determining the validity of fitted DRS 
models in their ability to control confounding. We investigated these methodological questions 
using Monte Carlo simulations and empirical data. The empirical analyses included 20% and 1% 
samples of Medicare claims data to compare the new oral anticoagulant dabigatran with 
warfarin in reducing the risk of combined ischemic stroke and all-cause mortality in older 
populations. 
When PS distributions are separated, DRS matching can improve the precision of effect 
estimates and allow researchers to evaluate the treatment effect in a larger proportion of the 
treated population. However, accurately modeling the DRS can be challenging compared to the 
PS. When evaluating the validity of DRS models, measures of predictive performance do not 
always correspond well with reduced bias in treatment effect estimates. Calculating the pseudo 
bias within a “dry run” analysis can provide a more direct measure for assessing the ability of 
fitted DRS models to control confounding.  
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CHAPTER 1 
BACKGROUND AND SPECIFIC AIMS 
1.1 Specific Aims 
Controlling large numbers of confounding variables presents unique challenges 
when evaluating new treatments in comparative effectiveness research. Summary scores, 
which reduce covariate information to a single dimension, have become increasingly 
popular for controlling large numbers of baseline covariates. The propensity score, defined 
as the conditional probability of treatment given a set of measured covariates, has become 
the most widely used summary score in pharmacoepidemiologic research.1, 2 It has been 
hypothesized, however, that modeling the PS during early periods of treatment 
introduction can be difficult as the number of individuals receiving the new treatment can 
be small and factors affecting treatment assignment can change rapidly during early periods 
of dissemination.3, 4    
An alternative summary score to the PS is the prognostic score, also known as the 
disease risk score (DRS). Instead of modeling covariate associations with treatment, the DRS 
models the relationship between covariates and the potential outcome under the control or 
comparator treatment.5-7 Because factors affecting disease risk are more stable over time, it 
has been proposed that modeling the DRS within historical data prior to treatment 
introduction can provide an alternative to the PS for controlling large numbers of covariates 
when evaluating new treatments.3 However, DRSs have not been widely used and the 
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validity and potential benefits of a historically estimated DRS remain unclear. In this study 
we used both Monte Carlo simulations and empirical data to examine the benefits of using 
a historically estimated DRS for controlling large numbers of covariates when evaluating 
new treatments. We further develop and evaluate methods for assessing the validity of DRS 
models directly in their ability to control for confounding. Empirical analyses focused on 
comparing of the new oral anti-coagulant dabigatran with warfarin in preventing combined 
ischemic stroke and all-cause mortality using Medicare claims data. There has been recent 
interest in the use of new oral anticoagulant drugs as an alternative to warfarin for patients 
with atrial fibrillation.8-10 Although clinical studies evaluating these new drug classes have 
shown promising results,10 their comparative effectiveness in real world patient populations 
remain largely unknown. With limited data at the beginning of drug approval, estimation of 
the PS as a function of large numbers of covariates can be problematic. In contrast, 
estimating the DRS within historical data could allow researchers to effectively control for 
large numbers of covariates immediately after drug approval, when data on safety is most 
important. Improved methods for confounding control during early periods of drug 
approval and evolving drug therapies can enhance treatment decisions for healthcare 
providers and the patient community. 
Aim 1: Use both Monte-Carlo simulations and empirical analyses to better 
understand potential benefits of using a historically estimated DRS when controlling large 
numbers of confounding variables during early periods of drug approval. The empirical 
analysis will focus on evaluating the comparative effectiveness of the new oral 
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anticoagulant medication dabigatran compared with warfarin in preventing ischemic stroke 
and all-cause mortality in patients with atrial fibrillation in the Medicare population.   
Rationale: There remains little evidence and understanding of the benefits of a 
historically estimated DRS compared with traditional PS methods in practice. It remains 
unclear what specific advantages the DRS provides over traditional PS methods. 
Aim 2: Use both simulations and substantive analyses to develop and compare novel 
strategies for evaluating risk models in their ability to control for confounding. 
Rationale: Accurately modeling the DRS presents unique challenges that are not 
shared by traditional outcome regression modeling or PS estimation. These difficulties 
highlight the importance of evaluating the validity of the fitted risk model in its ability to 
control for confounding. The validity of fitted DRS models has primarily been assessed 
through measures of predictive performance which give an indirect assessment of the 
ability of the DRS to control for confounding. Recent methods that use the control 
population to create pseudo treatment and pseudo control groups have been proposed as a 
more direct measure for assessing the validity of risk models in terms of confounding 
control. It remains unclear what metrics are optimal for evaluating risk models. 
1.2 Comparative Effectiveness Research 
Randomized controlled trials (RCTs) are the gold standard for evaluating the 
performance of a treatment or drug.11 The strict design of RCTs, including randomization 
and blinding, ensures the internal validity and effective control of variables that may bias 
results. However, information provided by RCTs can be limited for real world clinical 
practice. RCTs can fail to detect rare outcomes and long-term effects due to smaller sample 
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sizes and shorter durations of treatment.12-15  RCTs can also have limited generalizability 
due to restrictions placed on study participation including age, comorbidity and co-
medication.13, 14 Further, RCTs often assess efficacy versus placebo rather than versus an 
alternative treatment for the same indication. 
Comparative effectiveness research has gained considerable attention in recent 
years. It is becoming increasingly recognized that RCTs cannot address every question 
regarding treatment decisions for patients in real world clinical practice. Large automated 
healthcare databases, such as administrative data and electronic medical records, are 
increasingly being used to evaluate drug performance and safety.15  Compared with RCTs, 
observational studies are better suited to provide information on drug utilization as well as 
benefits and harms of drugs in real world settings with populations covering a wide range of 
patient characteristics.11, 14, 15  Automated databases can provide valuable information on 
the real time performance of medical treatments. This is critical for the active surveillance 
of drug effects in real world populations.16 Observational studies using healthcare and 
administrative datasets complement RCTs to improve healthcare providers’ decisions 
regarding drug and treatment choices.15 However, the evaluation of drug effects using 
observational data is susceptible to both measured and unmeasured confounding that is 
caused by the lack of randomization. The validity of studies using automated databases is 
limited by the ability of current statistical and epidemiologic methods to effectively control 
for large numbers of confounding variables.   
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1.2.1 Current Methodological Limitations 
The continual development and application of novel methods is essential to reduce 
bias in observational studies and more accurately address important public health issues 
regarding drug effects and treatment decisions in real world populations. The development 
of improved methods for confounding control is particularly needed during early periods of 
drug approval.3  During these early periods, there is often rapid change over time in drug 
prescribing patterns or in the use of a treatment.4  New users of a recently approved drug 
will often have different patient characteristics than new users of the same drug after the 
drug has been on the market for an extended period of time. Such changes over early 
periods of drug approval present significant challenges for comparative effectiveness 
research and can make rapid response for drug safety difficult.  Developing improved 
methods to control for confounding during early periods of drug approval is needed to 
provide the best evidence for treatment decisions during these early stages.  
Standard methods for confounding control have traditionally consisted of multiple 
regression models.  Although useful in many situations, these methods are limited for 
studies involving large numbers of confounders due to computational complexity, the high 
likelihood of model misspecification and the limited ability to model more complicated 
functional relationships such as interactions and higher order terms for rare outcomes.7  To 
address these limitations, methods that collapse the information of a large number of 
covariates into a single-dimensional summary score and then use this summary measure for 
confounding control have become increasingly popular.1, 6, 17   
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1.3 Summary Scores and Causal Inference 
1.3.1 Counterfactual Framework 
The Neyman-Rubin counterfactual framework provides a formal framework for 
researchers to determine causal effects in both experimental and non-experimental 
studies.18-20 Under the counterfactual model for causal inference, each person in the study 
population has a potential outcome corresponding to each possible treatment level. For 
example, if   represents a dichotomous treatment, then    represents the potential 
response had the individual received treatment and    the potential response had the 
individual received the control or comparator treatment. In practice, only one of the 
potential outcomes is observed for each individual. The observed response,  , has the 
following relationship with the potential outcomes 
               . 
The treatment variable,  , is said to have a causal effect on the observed outcome, 
 , for a given individual if      . For a population of individuals,   has an average causal 
effect on   within the entire population if            , where       and       represent 
the expected or average value of the random variables    and    respectively.  
A fundamental obstacle in non-experimental studies is estimating treatment effects 
in the presence of confounding factors. If controlling for a set of baseline covariates,  , 
results in treatment assignment being independent of potential outcomes, then average 
treatment effects in the population are identifiable.19  Known as the strongly ignorable 
treatment assignment assumption, this condition is formally expressed as             
where  denotes independence of random variables and | denotes conditional on. 
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Heckman21 showed that when estimating the treatment effect on the treated, the strongly 
ignorable treatment assignment assumption is unnecessarily restrictive and the weaker 
condition,       , is sufficient.  Known as the weakly ignorable treatment assignment 
assumption, this condition is sufficient to identify average treatment effects on the treated 
population.5, 21  
1.3.2 Propensity Score Methods 
    For a dichotomous treatment,  , the propensity score is defined as the conditional 
probability of treatment assignment given a set of baseline covariates,  . Formally 
expressed as           , Rosenbaum & Rubin1 show that conditioning on the PS 
results in covariates being independent of treatment assignment, formally denoted as 
        . If treatment assignment is strongly ignorable given a set of baseline 
covariates, i.e.            , Rosenbaum & Rubin
1 show that treatment assignment is 
strongly ignorable given the PS, i.e.               . This independence allows for the 
identification of average treatment effects in the full study population or average treatment 
effects in subgroups of the study population, e.g., the treated population. If treatment 
assignment is weakly ignorable, i.e.       , then conditioning on the propensity score 
satisfies            allowing for the identification of average treatment effects in the 
treated population. 
The development and advancement of PSs in various applications and settings has 
been a key factor for improved methodological standards and validity when evaluating drug 
effects in non-experimental settings. However, the performance of PSs is limited in certain 
settings. It has been hypothesized that PSs may not perform well for studies involving rare 
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or emerging treatments.22  Factors affecting treatment assignment are not necessarily 
biological in nature and are more likely to vary and change over time compared to factors 
that affect the outcome or disease.3, 6, 7 For example, physicians becoming more familiar 
with a new treatment may extend the indication to patients with less severe disease or 
more severe co-morbidities.  Other situations where transient factors affect indication for 
treatment include a newly approved treatment quickly diffusing through the market and 
the issuance of black box warnings.  Modeling the PS can potentially be difficult when 
factors affecting treatment assignment change over short periods of time.   
The PS is also not a natural measure to evaluate treatment effect heterogeneity. 
When making treatment decisions, clinicians are almost always concerned about how the 
effect of a treatment varies over various patient profiles affecting the risk for the outcome 
of interest (e.g., 10 year risk for cardiovascular disease based on the Framingham risk 
score).  Although the PS allows us to detect and account for treatment effect heterogeneity, 
it does not provide the best information for health care providers in determining what 
subgroups of the patient population are most likely to benefit from a given treatment 
regime.   
1.3.3 Disease Risk Score Methods 
The disease risk score (DRS) has been shown to be a valid alternative to PSs for 
controlling large sets of confounders.5, 7, 23, 24 Originally introduced by Peters in 194125 as a 
way to reduce dimensionality when matching, the DRS has been used by a variety of 
researchers to control for confounding and assess treatment effect heterogeneity.26, 27 The 
DRS is similar to the PS in that the DRS summarizes the information of a large number of 
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variables with a single-dimensional score.27  Unlike PSs, however, DRSs summarize the 
associations of baseline covariates with the potential outcome under the control therapy 
instead of treatment, i.e., the risk for the outcome.   
Despite the early introduction of DRSs, their use was inhibited in part due to an early 
study by Pike, et al.28 that examined their statistical properties.6, 28  Pike demonstrated that 
adjustment for the DRS can result in exaggerated statistical significance of effect 
estimates.28 After reexamining these findings, Cook & Goldman29 found that this 
exaggeration is small except when there is a very strong correlation between confounders 
and the exposure (correlation coefficient exceeding 90%), which is unlikely to occur in 
practical settings.6, 7, 29 Leacy further explains that this exaggeration in statistical significance 
is due to issues of model misspecification rather than the statistical properties of the DRS.30 
Recently, Hansen5 has solidified the theoretical foundation for the use of DRSs in 
causal inference. Hansen showed that the DRS acts as a prognostic balancing score that can 
yield valid effect estimates with a causal interpretation.5  Formally Hansen defines the 
prognostic score, or disease risk score, as any scalar or multi-dimensional function of   that 
satisfies the condition          .
5 In other words, conditioning on the DRS results in a 
form of covariate balance where the potential response under control is independent of a 
set of measured covariates,  . If the outcome follows a generalized linear model, Hansen5 
shows that one possible prognostic score, or DRS, is the linear predictor of   , or the 
conditional mean of    given   (i.e.,        ). Hansen
5 further shows that if treatment 
assignment is weakly ignorable given a set of baseline covariates, i.e.       , then 
conditioning on the DRS is sufficient to satisfy           allowing for unconfounded 
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estimates of the treatment effect in the treated population through stratification or 
matching on the DRS.  
Using simulations, Arbogast and Ray7 evaluated the properties of effect estimates 
when applying DRSs. Their study showed the DRS to perform similar to PSs and outcome 
regression models for the settings evaluated.7  Stürmer et al.24 and Cadarette et al.31  used 
data from Medicare recipients to evaluate the performance of disease risk scores compared 
to PS methods and traditional outcome regression in real world settings. In these examples, 
results were similar from the application of DRSs, PSs, or traditional multivariable 
regression.  
Due in part to this recent theoretical work and evaluation of the properties of DRSs 
using both simulations and empirical data, there has been increased interest in the 
application of DRSs to evaluate drug performance.23  Although generally not superior to PSs, 
the DRS can be advantageous to PSs for controlling confounding in certain settings.24 For 
example, studies with rare exposures (e.g. emerging therapies) and studies involving 
multiple therapies can benefit from DRSs which model covariate associations with the 
outcome rather than treatment.7, 31 Further, DRSs provide a natural measure to evaluate 
treatment effect heterogeneity. Evaluating treatment effect heterogeneity across the 
distribution of disease risk provides a straightforward approach for clinicians to identify 
subgroups of patients that are most likely to benefit from the treatment, thereby improving 
treatment decisions made by healthcare providers.3  
Despite this recent attention, there remain many unanswered questions regarding 
the use of DRSs in practice.  A fundamental challenge in applying DRSs is understanding how 
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these summary measures should be estimated. Although various strategies for estimation 
have been proposed, there remains uncertainty regarding which estimation strategy is 
optimal in diverse settings. This uncertainty is particularly acute for studies using large 
administrative datasets to evaluate the comparative effectiveness of drugs because there 
have been relatively few applications of disease risk scores in these settings. Multiple 
researchers have expressed the need for further empirical and simulation studies to clarify 
the application of DRSs in real world practice.6, 31 
Traditionally, the DRS has been estimated in two ways. The first is to fit a regression 
model to untreated individuals within the cohort and then use this model to predict the 
disease risk for all individuals within the full cohort.  The second is to fit a regression model 
to the full cohort (both treated and untreated) as a function of baseline covariates and 
treatment, and then estimate the disease risk for each individual after setting treatment 
status to untreated.3, 5, 7  
Fitting the DRS to the full cohort benefits from increased sample size, but requires 
accurately modeling the relationship between the treatment and outcome.5 Hansen shows 
that when estimating the DRS within the full cohort, incorrectly modeling the modification 
of treatment by baseline covariates (i.e. disease risk) can result in estimated scores that 
carry information about the true treatment effect. This non-ancillarity in the estimated 
scores can obscure the effect estimate when used for stratified or matching analysis. 
Correctly modeling treatment effect heterogeneity by disease risk can be difficult, 
particularly for large numbers of covariates. Therefore, Hansen recommends using only the 
untreated cohort for estimation of the disease risk.5  However, accurate estimation of the 
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DRS using only the untreated cohort presents its own challenges. Fitting the DRS only within 
the untreated cohort can introduce bias by substantially increasing the potential for 
overfitting the model.3, 5  
 Recently, alternative strategies for estimating DRSs that use data from outside the 
defined new user cohort have been proposed.  Both Hansen and Glynn discuss potential 
advantages of using outside data to estimate the DRS.3, 5 Hansen explains that estimating 
the DRS within an alternate sample of controls can avoid the complications of overfitting 
that can occur when using same-sample estimation. Glynn suggests that out-of-sample 
estimation of the DRS can be particularly advantageous when evaluating evolving drug 
therapies because the first patient receiving the new treatment can be matched to a 
concurrent patient receiving the old treatment based on the estimated disease risk.3  
In contrast with predictors of treatment, factors that predict outcome or disease 
occurrence are more likely to be biological in nature and less likely to vary over time and be 
impacted by physician decisions which can be difficult to identify.3, 6 Because the DRS is 
likely to be stable over time and across populations, Glynn proposes that disease risk can be 
accurately estimated from either a separate population, or the same population but with 
historical data from a period prior to the current study period.3  
During early periods of drug approval, there is usually limited data to accurately 
estimate either the PS or DRS as a function of large numbers of covariates, particularly for 
studies involving rare outcomes or rare exposure. Further, during early periods of a newly 
introduced drug, a well-defined PS may not exist due to evolving factors affecting treatment 
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assignment. Out-of-sample estimation for the DRS potentially avoids these challenges by 
using a sample with sufficient data to accurately estimate the disease risk.  
While having the potential to improve confounding control for the early evaluation of 
treatment therapies, the performance and potential benefits of historical estimation of 
disease risk is not well established. Using observations, or information, from historical data 
can present important challenges. Covariate assessments and coding practices can change 
over time making a historically estimated DRS not generalizable to future time periods and 
populations.   
The challenges outlined above when estimating the DRS highlight the importance of 
evaluating the validity of fitted DRS models in their ability to control for confounding. If 
prognostic balance could be evaluated within the full study population, then measures of 
prognostic balance could be used to evaluate the validity of fitted DRS models in a similar 
way that measures of covariate balance across treatment groups are used to evaluate PS 
models. Prognostic balance, however, can only be evaluated within individuals receiving the 
comparator treatment where the potential outcome under control,   , is observed. It is 
unclear how well measures of prognostic balance within only the control group correspond 
to a reduction in bias in the estimated treatment effect. Measuring prognostic balance only 
within the comparator group can potentially reward models that are overfit to the control 
population. Further, in the presence of unmeasured confounding, the DRS does not result in 
prognostic balance within subgroups of treatment, but only marginally within the entire 
population.5, 32 Measures of prognostic balance only within the control population can 
potentially lead to an incorrect assessment of the specified DRS model.   
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The inability to evaluate prognostic balance within the full study population has led 
to researchers evaluating DRS models primarily through measures of predictive 
performance, such as the c-statistic and goodness of fit tests. However, it is unclear how 
well measures of predictive performance correspond with the ability of DRS models to 
control confounding. When fitting PS models, previous studies have shown that measures 
of predictive performance do not always correspond well with reduced bias in the 
estimated treatment effect.33, 34 Little attention has been given to determining what metrics 
are optimal for evaluating fitted DRS models. 
1.4 Anti-coagulant medications and cardiovascular disease in patients with atrial fibrillation 
 Atrial fibrillation (AF) is the most common cardiac dysrhythmia in the United States 
and is a growing public health concern.35, 36  AF is an established risk factor for stroke, 
cognitive dysfunction, and premature death.37-39 It has been estimated that AF accounts for 
up to 15% of strokes in people of all ages and up to 30% of strokes in people over 80 years 
of age.40, 41  Results from the Framingham Heart Study showed the prevalence of AF to be 
6% and estimated that the lifetime risk for developing AF is approximately 25% for both 
men and women 40 years of age and older.39 The Framingham Heart Study has further 
shown that the risk for AF increases with age.  As the elderly population increases in the 
United States, the prevalence of AF is expected to increase substantially over the next few 
decades.42  
 Standard practice for treating patients with AF includes treatment with an anti-
coagulant for the prevention of thromboembolic events.8 Long term oral anticoagulant 
treatment options for patients with AF have only included long-acting VKAs (warfarin).8 
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Warfarin has been the most widely used VKA and has been shown to decrease rates of 
stroke in patients with AF in several trials.8, 43  Warfarin reduces blood coagulation by 
inhibiting vitamin K-dependent clotting factors. However, the magnitude of the effect on 
these factors is variable and difficult to predict. Warfarin is a drug with a very narrow 
therapeutic window and pronounced inter- and intraindividual variation of effects on 
coagulation. Warfarin thus needs intense monitoring of its effects on coagulation based on 
the INR that needs to be kept within a narrow range. Both ineffectiveness (too low INR) and 
increased risk of bleeding (too high INR) are quite common. Consequently, AF patients 
being treated with warfarin need to be closely monitored to assure that patients are 
attaining an effective dose range. Several studies have shown that as many as 45% of 
patients on warfarin are not within the therapeutic range for a sufficient period of time.8, 10, 
44 Although most patients have been shown to benefit from warfarin, concern for these 
potential complications and adverse bleeding events has often led to an underuse of 
anticoagulant medications among persons with AF.45, 46 It is estimated that warfarin has 
only been used by 30-60% of appropriate patients with AF.45, 47, 48  
 New oral anti-coagulant medications that focus on inhibiting a specific factor in the 
coagulation pathway have recently been developed to overcome the shortcomings of 
warfarin.43 There are numerous oral anticoagulant agents in development. The most 
advanced in clinical research belong to two drug classes: direct thrombin inhibitors (DTIs) 
and factor Xa (FXa) inhibitors.8 Clinical studies evaluating these drug classes in patients with 
AF have shown promising results. Dabigatran, a direct thrombin inhibitor, showed reduced 
rates of stroke or systemic embolism in select patients with AF when compared to warfarin 
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in the RE-LY trial.49 The ROCKET-AF trial showed the oral FXa inhibitor Rivaroxaban to be 
noninferior to warfarin in reducing rates of stroke and produced no significant difference in 
the risk of major bleeding.41  In the ARISTOTLE randomized trial comparing the direct FXa 
inhibitor apixaban to warfarin in patients with AF, apixaban was also shown to be 
noninferior to warfarin in reducing stroke while resulting in fewer major bleeding events.50 
Unlike warfarin, clinical data have further shown that these novel agents have predictable 
pharmacokinetic, pharmacodynamics, and anticoagulant response thereby. The predictable 
performance of these newer agents reduces the need for dose adjustments and frequent 
monitoring of coagulation parameters.8, 9, 51 The abundant clinical data supporting the 
efficacy of these novel oral anticoagulant agents has led to the recent FDA approval of 
dabigatran in October 2010, rivaroxaban in November 2011, and apixaban in December 
2012. In addition to these oral anticoagulants, there are several additional novel 
anticoagulant agents in advanced development.   
 As novel anticoagulants become more widely used, it is possible that there will be a 
paradigm shift in the prescribing of anticoagulation treatments for patients with AF.8 
Although clinical data suggest increased potential for achieving an effective dose range with 
these newer agents without the need for frequent monitoring, the implications on 
population level practice have not been adequately evaluated. Ansel52 discusses limitations 
of these clinical trials highlighting important inclusion/exclusion criteria that may not 
generalize to these new oral anticoagulants having the same performance in real world AF 
patients. A systematic review comparing new oral anticoagulants (dabigatran, rivaroxaban 
and apixaban) to warfarin concluded that these new agents had a lower risk for fatal 
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bleeding and hemorrhagic stroke, but an increased risk for gastrointestinal bleeding, a more 
common event in the elderly.10 Differential performance of these new anticoagulants 
between young and elderly populations is not well established.  
Many clinicians acknowledge that there are gaps in the current understanding of 
how these new medications perform in clinical practice.52-54 Ansell52 asserts that there are 
enough unknowns regarding the effects of these new oral anticoagulants that health care 
providers and patients should be cautious when using these medications as first line 
treatment. Observational research has the potential to supplement information provided by 
the randomized trials and improve our understanding of these new anticoagulants in real 
world practice and diverse patient populations. In a systematic review conducted by Adam 
et al,10 the authors found that the observational literature on adverse events of new oral 
anticoagulants is sparse, consisting only of case reports. We seek to improve the 
information regarding the performance of recently introduced novel oral anticoagulant 
medications by using the previously described methods to thoroughly investigate their 
performance in elderly populations using Medicare data.  
1.4.1 Early Evaluation of New Oral Anticoagulant Drugs for Patients with Atrial Fibrillation  
Due to the very recent approval of these new oral anticoagulants, their evaluation in 
non-experimental settings is difficult, in part due to the limited data available to control for 
large sets of confounders. Out-of-sample estimation methods for disease risk are 
advantageous because these methods can potentially allow for the control of a large 
number of risk factors at the start of drug introduction. While Medicare data do not capture 
some important clinical variables, including blood pressure, they offer major advantages for 
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this kind of research based on the population-based nature (real world) and the ability to 
evaluate clinically relevant outcomes rather than intermediates within a very short time 
(because of the overall size of the population).55, 56 This will potentially allow researchers to 
effectively evaluate the comparative effectiveness of these newer medications at earlier 
periods than previous methods.  
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CHAPTER 2 
METHODS 
2.1 Study Population  
This study consisted of older individuals ages 65 years and older who were 
beneficiaries of the Medicare system. Medicare is a national insurance program for all 
Americans over the age of 65.  Because all elderly Americans are entitled to these benefits, 
individuals receiving Medicare are likely to be representative of the general health care 
utilization of elderly adults in the US population. However, the Medicare data made 
available for research is limited to parts A, B, and D. Medicare part C, which includes 
Medicare Advantage plans, is administered by private insurance companies and is not made 
publicly available. Medicare part C covers approximately 25% of all Medicare beneficiaries 
and contains individuals who tend to have higher socioeconomic status. Furthermore, the 
study populations for the research questions in this study excluded individuals who did not 
participate in Medicare part D. The exclusion of Medicare part C recipients and individuals 
who do not participate in part D may affect the study population to be more representative 
of Medicare beneficiaries of lower socioeconomic status. 
The Medicare data from the Center for the Medicare and Medicaid Services (CMS) 
Chronic Condition Data Warehouse from 2007 to 2012 are available at UNC. The CCW files 
include annual enrollment summary, inpatient, outpatient, skilled nursing facility, carrier 
(physician office visit), hospice, home healthcare agencies, durable medical equipment files 
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and prescription Part D event files. The prescription Part D files include the national drug 
code of the medication, service data, strength of the medication, days of supply, quantity 
dispensed, encrypted and unique prescriber identifier, unique and encrypted pharmacy 
identifier, generic drug name, and the benefit phase of the Part D event. All CCW files are 
linked by an encrypted and unique CCW identifier number for each beneficiary. We used 
100% of patients nationwide who meet the inclusion and exclusion criteria. 
2.2  Study Design  
We included individuals who were continuously enrolled in the Medicare data at 
least 12 months before and through the end of the study period. A new user cohort study 
design was used to evaluate the described research questions.11 We identified Rx claims for 
dabigatran and warfarin within Medicare A, B, and D claims data. We determined periods of 
new use after a pre-specified washout period. New users of dabigatran who had a 
prescription claim for the comparator drug during the specified washout period were 
excluded. We identified new users of dabigatran and warfarin between the years 2010-
2012. The start of this time period corresponds to FDA approval for dabigatran. 
We applied a new user cohort design when evaluating the previously described 
research questions to mitigate both measured and unmeasured confounding caused by 
indication for treatment and healthy users. Confounding caused by indication for treatment 
and healthy-users are two primary sources of bias in comparative effectiveness research. 
New user designs reduce the potential for healthy user bias by excluding prevalent users.57 
Prevalent users of a drug at baseline of follow-up are more likely to have systematic 
differences in the distributions of unmeasured risk factors for the outcome compared to 
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new initiators of the drug.11, 57 In each of the analyses, we further reduced the magnitude of 
confounding caused by indication for treatment by comparing the defined exposure to an 
active comparator with similar indication.58 
All decisions on exclusion criteria for cohort participation were made prior to 
treatment initiation and follow-up. Measured confounders were controlled at baseline 
using propensity score matching and disease risk score matching.  
2.3 Choice of Outcomes 
 We considered a combined outcome of ischemic stroke and all-cause mortality. 
Ischemic stroke was defined as hospitalization with diagnostic codes in the principal or 
secondary positions (Primary Dx 430-434). Birman-Deych, et al59 demonstrated that ICD-9 
codes for coronary artery disease, stroke, heart failure, and hypertension had high 
specificity (>0.95), low sensitivity (<0.76), and a positive predicted value of 0.95 within the 
Medicare Part A data. They further demonstrate that miscoding of ischemic stroke events as 
hemorrhagic events was rare. Similar findings have been found by other studies evaluating 
the validity of ICD-9 codes in other large administrative databases.60  
2.4 Variable Selection 
For the empirical analysis, we selected a high-dimensional set of covariates using an 
algorithm that is similar in concept to the high-dimensional PS.61 We first selected a reduced 
set of covariates a priori using expert knowledge. We then included an additional 200 
empirically selected covariates that were identified within Medicare files containing 
medication claims, inpatient and outpatient diagnostic codes and procedural codes. When 
selecting the 200 additional covariates, we first identified the top 200 most prevalent codes 
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within each data dimension of the Medicare data (codes with a prevalence greater than 0.5 
were subtracted from 1). Among the codes selected, we then identified the top 200 codes 
based on the strength of their univariate association (odds ratio) with the outcome.  
2.5 Monte Carlo Simulations 
We used Monte Carlo simulations to better understand and evaluate potential 
benefits of DRS matching vs PS matching for Aim 1. Simulations were also used in Aim 2 to 
compare various measures for evaluating the validity of the specified DRS models.  
2.5.1 Simulations for Aim 1 
The simulated causal structure for Aim 1 was motivated by the empirical example 
comparing new-users of dabigatran with warfarin in preventing ischemic stroke and all-
cause mortality. We simulated 100 baseline covariates to reflect settings involving high-
dimensional sets of covariates. Baseline covariates included a mixture of both continuous 
and dichotomous random variables. We simulated a dichotomous treatment as a function 
of the 100 baseline covariates. We then simulated a dichotomous outcome as a function of 
the 100 baseline covariates and treatment.  
We considered four scenarios where we varied the sample size and the strength of 
the effects of covariates on both the treatment and outcome. We allowed coefficients to be 
both positive and negative to reflect practical settings where baseline covariates induce 
confounding in both directions. We implemented the PSs and DRSs using 1 to 1 caliper 
matching where calipers were defined as .01 standard deviations of the respective PS or 
DRS distribution. We compared the performance between PS and DRS matching by 
calculating the bias, defined as the expected value of the difference between the effect 
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estimate and the true effect, by taking the mean of this difference over all simulation runs.  
The mean squared error (MSE) was calculated by taking the mean of the squared bias over 
all simulation runs. We evaluated the precision of the effect estimates using the empirical 
standard deviation of the distribution of the treatment effect estimates across all simulation 
runs.  
2.5.2 Simulations for Aim 2 
We created a variety of populations where we varied the causal structures, covariate 
distributions and covariate associations.  We evaluated scenarios which include rare 
outcomes, rare exposures and small sample sizes.  In comparison to the complexities of real 
world data, these simulated populations were simplified in order to obtain a general 
understanding of the statistical properties and performance of various measures for 
evaluating the validity of DRS models. Simulations allow us to identify specific settings and 
parameters which systematically affect the performance of each of the described methods 
for confounding control.   
2.6  Aim 1: Evaluating Potential Benefits of the Disease Risk Score 
We will evaluate potential benefits of matching on the DRS compared to matching 
on the PS. Potential benefits of the DRS remain largely unclear with few studies 
demonstrating the application of DRSs in large database research.  
2.6.1 Overlap in the distribution of disease risk across treatment.  
Strong channeling can create separation in the PS distribution across treatment 
groups during early periods of drug approval. This can reduce the number of individuals 
who can be compared or matched on the PS and limit the ability to evaluate the treatment 
24 
 
effect within a large portion of treated patients, particularly when controlling for large 
numbers of covariates.  
A theoretical advantage of the DRS that has not been discussed is that the degree of 
overlap in the DRS distributions across treatment groups will always be as at least as large 
as the overlap in the PS distributions across treatment groups. Greater overlap in the DRS 
distributions can potentially allow for a greater number of individuals to be compared when 
matching on the DRS compared to matching on the PS.  
The reason for greater overlap in the distribution of disease risk across treatment is 
because of differences in the balancing properties of the PS compared with the DRS. 
Matching treatment groups on the PS is a more restrictive condition then matching 
treatment groups on the DRS. Matching on the DRS does not require covariates to be 
balanced across treatment groups and can include individuals who systematically have 
differing covariate distributions across treatment groups, but similar overall risk for the 
outcome.5  
More formally, because matching on the PS renders baseline covariates 
independent of treatment assignment within the matched population, any function of 
baseline covariates will also be independent of treatment assignment including the DRS. 
Formally,  
                  
since the DRS is simply a function of  . Rosenbaum and Rubin show that 
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implying that                   . In other words, once we condition on the PS, the 
covariate vector,  , or any function of  , including the DRS, does not provide any additional 
information about treatment assignment.  
2.6.2. Controlling for instrumental variables  
Including instrumental variables within the PS can also increase the separation in the 
PS distribution across treatment groups further limiting the number of patients that can be 
matched or compared. In addition, both theory and simulations have shown that controlling 
for variables that do not affect the outcome except through treatment (instrumental 
variables) can reduce the precision of effect estimates and amplify bias caused by 
unmeasured confounders.62, 63  
Unmeasured confounding is a fundamental obstacle in pharmacoepidemiology and 
observational research in general. Primary sources of unmeasured confounding in 
comparative effectiveness research arise from 1) confounding by indication for treatment 
and 2) confounding caused by frailty.57, 64, 65 For example, physicians’ treatment decisions 
may be based on an evaluation of the patient’s health status and prognosis, the patient’s 
theoretical response to treatment, the physician’s past experience with the treatment, or 
an assessment of the patient’s ability and willingness to undergo the treatment (e.g., take a 
medication as prescribed).66 Further, patients who initiate a preventive medication may be 
more likely than other patients to engage in other healthy, prevention-oriented behaviors 
leading to bias known as the healthy user effect.67, 68 Conversely, patients in whom the 
expected benefit is unlikely to materialize (e.g., because of overwhelming competing risks) 
are less likely to be started on preventive therapies and more likely to stop preventive 
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therapies. These types of confounding usually result in the distributions of unmeasured 
covariates being systematically different between treatment groups.  
For studies involving large numbers of covariates, identifying instrumental variables 
can be challenging. Pharmacoepidemiologic and medical studies utilizing automated 
databases often involve large numbers of potential covariates that have not been selected 
with a specific research question in mind and where a multitude of factors other than the 
prognosis strongly influence treatment decisions.  
While the potential for including instrumental variables is highest for a model 
predicting treatment (the PS), it is important to realize that it is not generally avoided by 
modeling the risk for the outcome. Once we condition on treatment (either by modeling 
treatment or by restricting to the untreated), instrumental variables will become associated 
with the outcome via the unmeasured confounders. The DRS, if estimated within the study 
population, will also tend to be affected by bias amplification in the presence of 
unmeasured confounders.  
By modeling covariate associations with the outcome within historical data prior to 
treatment introduction, the DRS implicitly avoids controlling for instrumental variables.32 
Out-of-sample estimation of DRSs is therefore likely to minimize bias caused by 
unmeasured confounding compared with PS methods or outcome regression models, 
including conventionally estimated DRSs. These potential advantages of greater overlap in 
the DRS distribution across treatment groups and the avoidance of controlling for 
instrumental variables can potentially improve the precision of effect estimates by allowing 
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for a larger proportion of treated individuals to be compared during periods where the 
number of individuals receiving the new treatment therapy can be small. 
2.7  Aim 2: Model Validation  
2.7.1. Validation of Propensity Score Models 
We will evaluate the validity of the specified PS models by calculating the average 
standardized absolute mean difference (ASAMD) of the measured covariates across 
treatment groups, where the ASAMD for a single covariate is defined as 
 
  
     
 
  
    
  
   
  
   
    
    
    
 
where 
     the value of   for the i
th individual in the treatment group, 
    number of individuals in the treatment group, 
  
   sample variance of   in the treatment group. 
The ASAMD is a straightforward measure to summarize covariate balance and has 
been shown to perform well compared to other measures of covariate balance when 
evaluating the validity of PS models in their ability to control confounding.69, 70  
2.7.2. Validation of Disease Risk Score Models 
Hansen5 showed that unlike propensity balance where covariates are balanced with 
respect to treatment within the entire study population, conditioning on the DRS results in 
‘prognostic balance’ where covariates are balanced with respect to the potential outcome 
under the comparator treatment. Because this potential outcome is not observed for each 
individual in the study cohort, it is not possible to evaluate the validity of DRS models 
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directly in terms of prognostic balance across the entire population. It remains unclear what 
measures are optimal for evaluating risk models in their ability to control for confounding.  
Within the simulated populations, we evaluated the correlation between various 
measures for assessing the validity of fitted DRS models and bias in the estimated treatment 
effect. We evaluated the predictive performance of the estimated DRSs by assessing the 
calibration and discrimination of the predicted values. The calibration was assessed using 
the Hosmer-Lemeshow goodness of fit test71 defined as  
   
       
 
           
     
 
 
   
 
where 
    number of observations in the g
th group, 
          observed number of cases in the g
th group, 
          expected number of cases in the g
th group. 
We also evaluated the calibration of predicted values by calculating the prediction 
error for each DRS model. The mean prediction error was calculated as  
    
 
        
  
 , 
where     the observed response for individual    and    is the predicted response from 
the risk model.  
We assessed the discrimination of the predicted values by calculating the c-statistic 
defined as the area under the receiver operating characteristic curve.72  This curve is a plot 
of the true positive rate (sensitivity) against the false positive rate (1-specificity) and is 
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calculated by comparing all disjoint pairwise combinations of individuals and calculating the 
proportion of those combinations where the predicted value for the individual with the 
event is higher than the predicted value for the individual with no event.  
Finally, we evaluated the performance of a resampling method proposed by 
Hansen73 that assesses the validity of DRS models in their ability to control for confounding 
rather than their predictive performance. This strategy draws weighted samples from the 
control population to create “pseudo treatment” and “pseudo control” groups so that the 
distribution of covariates across the pseudo treatment groups are representative of those 
across the treatment groups in the original study cohort. With no treatment effect 
separating the pseudo treated and pseudo control groups, the fitted DRS models can be 
evaluated directly in their ability to control for confounding within the pseudo population.  
The pseudo treatment and pseudo control groups are created as follows: 
1. Estimate the propensity score for each individual in the study population. 
2. Create a pseudo treatment group by taking a weighted sample of         
individuals from the control population with weights proportional to the 
odds of receiving treatment. Formally,  
   
    
        
 
where    weight for individual   and       propensity score for 
individual  .  
3. Sampling in step 2 can be done with or without replacement. When sampling 
with replacement, a pseudo control group is created by sampling         
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individuals from the control population with weights equal to one. If 
sampling without replacement, the pseudo control group is created by 
simply taking individuals from the control population that were not selected 
for the pseudo treatment group in step 2 (the complement of the pseudo 
treatment group).  
 Sampling the pseudo treatment group with replacement is similar in concept to 
standardized mortality ratio weighting where a subset of the control population is weighted 
so that the propensity score distributions between the weighted control group (which in 
this case is the pseudo treatment group) and treatment group in the original study cohort 
are exchangeable. Because         , where   is a set of measured baseline covariates 
and      is the propensity score, this exchangeability on the PS implies exchangeability on 
the measured covariates  . With the covariate distributions across the pseudo treatment 
groups being representative of those within the actual treatment group, we can perform a 
“dry run” by fitting the DRS within the pseudo control group, or a historical set of controls, 
and then evaluating its ability of the fitted model to control for confounding within the full 
pseudo population. Since the degree of confounding within the pseudo population should 
be representative of confounding in the original study cohort, DRS models that successfully 
control for confounding within the pseudo population should also control for the same 
measured confounders within the original study cohort.  
 When sampling with replacement, the same individuals can potentially be sampled 
many times over. Sampling without replacement avoids this problem, but requires a more 
complicated sampling scheme to take into account that the sampling probabilities for each 
31 
 
individual change with each draw from the finite population. Chen & Dempster74 describe a 
method to maximize information when taking a weighted sample without replacement 
from a finite population. In this paper, we restricted analyses to sampling with replacement. 
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CHAPTER 3 
 
USING DISEASE RISK SCORES TO CONTROL LARGE NUMBERS OF COVARIATES IN 
COMPARATIVE EFFECTIVENESS RESEARCH OF NEW TREATMENTS 
 
3.1 Introduction 
Evaluating the comparative effectiveness of newly introduced treatments presents 
unique challenges in pharmacoepidemiologic research. The propensity score, defined as the 
conditional probability of treatment given a set of observed covariates, has become a 
standard tool for controlling large numbers of confounding variables.1, 2 However, 
accurately modeling the PS for a new treatment can be difficult if the treated population is 
small or factors affecting treatment assignment change rapidly.3, 4  
In a recent paper, Glynn et al.3 proposed using an alternative covariate summary 
score, the disease risk score (DRS), to control for confounding in settings involving new 
treatments. Unlike the PS, which models covariate associations with treatment, the DRS 
models covariate associations with the outcome within the control or comparator 
treatment group. Glynn et al. argued that factors affecting disease risk are more likely to be 
stable over time than are factors affecting treatment, potentially simplifying the estimation 
of the DRS compared to a time-varying PS. Glynn et al. also advocated using data collected 
prior to the introduction of the new treatment to avoid overfitting and provide ample data 
when fitting rich prediction models. 
33 
 
Little evidence exists to confirm the theoretical advantage of a historically estimated 
DRS over a traditional PS when evaluating new treatments. A number of studies have shown 
that simply fitting time-specific PS models can perform well when the indication for 
treatment changes rapidly over time.4, 75 Further, the limitations of the PS when the number 
of exposed individuals is small are not well understood. Previous studies have also shown 
that overfitting the PS model does not necessarily compromise confounding control.76 
There remain few examples demonstrating the application of a historically estimated DRS 
when evaluating new treatments. Potential advantages and challenges of using DRSs in 
these settings remain unclear. 
In this paper, we use both simulations and an empirical example to compare the 
performance of the DRS with that of the PS when controlling large numbers of covariates in 
settings involving newly introduced treatments. We discuss both challenges and potential 
advantages of using the DRS for confounding control as well as required assumptions for 
using historical data to model the DRS. We then evaluate the performance of DRS matching 
with PS matching in an empirical example where we compare the new oral anticoagulant 
dabigatran with warfarin in preventing ischemic stroke and all-cause mortality in patients 
diagnosed with atrial fibrillation (AF) in the Medicare population.  
3.2 Background 
In comparative effectiveness research, investigators are often interested in 
comparing two alternative treatment therapies. Following Rubin’s77 description of the 
counterfactual framework, let    represent the potential response had the individual 
received the treatment of interest and    the potential response had the individual received 
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the comparator or control treatment. In practice, only one of these potential outcomes is 
observed for each individual.18, 19  
Hansen5 formally defines the DRS as any scalar or multidimensional function of a set 
of baseline covariates,  , that, when conditioned on (e.g., matching or subclassification), 
results in   being independent of   . In the absence of unmeasured confounding, this 
independence is sufficient to identify average treatment effects in the treated population.5, 
21 If the outcome follows a generalized linear model, one possible DRS is the linear predictor 
of   , or the conditional mean of    given   (i.e.,        ). Because    is observed only for 
individuals receiving the comparator treatment, in practice the DRS must be estimated 
indirectly for the treated population. 
Challenges when modeling the DRS. The DRS has typically been estimated in two 
ways. The first is to fit a regression model within the cohort of individuals receiving the 
comparator treatment and then extrapolate this model to predict disease risk for the full 
cohort. The second is to fit a regression model for the full cohort (i.e., both treatment and 
comparator groups) as a function of baseline covariates and treatment, and then estimate 
the disease risk for each individual after setting treatment status to zero.3, 5, 7, 27, 31 Fitting 
the DRS to the full cohort benefits from increased sample size, but requires accurately 
modeling the relation between treatment and outcome. Small misspecifications in the full-
cohort DRS model can introduce bias by resulting in estimated scores that are non-ancillary, 
or carry information about the treatment effect.5, 30 Consequently, Hansen5 recommends 
using only the control population when fitting the DRS model. Leacy30 explained that using 
only the control population when modeling the DRS tends to result in estimated scores that 
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are more robust to model misspecification. Fitting the DRS only among individuals receiving 
the comparator treatment, however, can lead to overfitting,5 which results in 
overestimating disease risk for high-risk comparator patients and underestimating disease 
risk for low-risk comparator patients. Such overfitting can lead to apparent treatment effect 
heterogeneity over the distribution of disease risk and potentially bias overall effect 
estimates.3, 5  
Both Hansen5 and Glynn et al.3 have proposed using controls from a period prior to 
the current study to fit the DRS model. Glynn et al. suggested that estimating the DRS with 
historical data can be particularly advantageous in pharmacoepidemiologic studies using 
large administrative healthcare databases to evaluate newly introduced treatments or 
evolving drug therapies. This approach can avoid overfitting the risk model to the 
comparator group within the study cohort, but assumes that the effects of risk factors on 
the outcome, surveillance of individuals, and coding practices do not change over time. 
Violation of these assumptions could result in fitted DRS models that are not generalizable 
to the study population.  
Potential benefits of matching on the DRS. A theoretical advantage of the DRS that 
has not been widely discussed is that the degree of overlap in the distribution of disease risk 
across treatment groups will always be at least as large as the overlap between the PS 
distributions. This is due to the fact that matching on the PS is more restrictive than 
matching on the DRS. Matching on the PS will only include individuals who, in expectation, 
have similar covariate distributions across treatment. Matching on the DRS, however, will 
not only include individuals who, in expectation, have similar covariate distributions across 
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treatment, but can also include individuals who systematically have differing covariate 
distributions across treatment, but similar overall risk for the outcome.5 More formally, 
once covariates are independent of treatment, then any function of baseline covariates, 
including the DRS, will also be independent of treatment. Therefore, PS-matched treatment 
groups will be balanced on the DRS in expectation. However, because the DRS does not 
balance covariates with respect to treatment, but only with respect to   , DRS-matched 
groups may not be balanced on the PS. The potential for greater overlap in DRS 
distributions across treatment groups may allow a larger percentage of the treated 
population to be compared when matching on the DRS versus the PS.  
3.3 Simulation Study: an Illustrative Example 
We simulated a causal scenario that was motivated by an empirical example 
(described below) comparing dabigatran with warfarin in preventing ischemic stroke and 
all-cause mortality among new users. We simulated 100 baseline covariates. As in most 
pharmacoepidemiologic settings, the majority of these baseline covariates were 
dichotomous (simulated as binomial random variables). We simulated a dichotomous 
treatment and a dichotomous outcome according to equations 3.1 and 3.2.  
                                                                          [3.1]    
                                                                     [3.2]        
We considered four scenarios where we varied the sample size and the strengths of 
covariate-treatment and covariate-outcome associations. In scenario 1, coefficients in 
Equations 1 and 2 were selected randomly from uniform distributions so that the effects of 
covariates on both the treatment and outcome were mild. In Scenarios 2 and 3, coefficients 
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were selected to allow for moderate and strong effects, respectively, on the treatment and 
outcome. In Scenario 4 we included treatment effect heterogeneity to demonstrate how 
effect estimates can differ when different numbers of individuals are matched on the PS 
versus the DRS. We allowed coefficients to be both positive and negative to reflect practical 
settings where baseline covariates induce confounding in both directions. We simulated 
each scenario with sample sizes of 10,000 and 1,000. 
We measured the performance of DRS and PS matching in three ways. We 
calculated the bias, defined as the expected value of the difference between the effect 
estimate and the true effect, by taking the mean of this difference over all simulation runs.  
The mean squared error (MSE) was calculated by taking the mean of the squared bias over 
all simulation runs. To evaluate precision, we estimated the standard error using the 
empirical standard deviation of the distribution of the treatment effect estimates across all 
simulation runs.  
3.4 Simulation Results 
For simulation scenarios not involving treatment effect heterogeneity, Figures 3.1 
and 3.2 show the PS and DRS distributions by treatment group for one simulation run with a 
sample size of 10,000 (Figure 3.1) or 1,000 (Figure 3.2). As expected, the degree of overlap 
(i.e., area of overlapping region) between the DRS distributions was always larger than the 
degree of overlap between the PS distributions. Varying the sample size and the strengths 
of covariate-treatment and covariate-outcome associations affected the overlap in PS 
distributions more strongly than it affected the overlap in DRS distributions (Figures 3.1 and 
3.2).  
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Table 3.1 shows that, for every scenario, a larger percentage of the treated 
population could be matched on the DRS versus the PS because of the greater overlap in 
DRS distributions (percent matched was approximately 100 for DRS matching and ranged 
from 98.8 to 47.6 for PS matching). The DRS-matched estimate generally had greater 
precision and lower MSE compared to the PS-matched estimate, with MSE ranging from 
0.02 to 0.72 for DRS matching and 0.04 to 0.72 for PS matching (Table 3.1). Both DRS and PS 
matching resulted in approximately unbiased estimates for scenarios where there was no 
treatment effect heterogeneity. In the presence of treatment effect heterogeneity, 
matching on the DRS resulted in a more accurate evaluation of the treatment effect within 
the entire treated population (Table 3.1).  
3.5 Empirical Study: Dabigatran vs Warfarin in Patients with Atrial Fibrillation 
We compared the performance of dabigatran versus warfarin in an elderly 
population using linked Medicare Parts A (hospital), B (outpatient), and D (pharmacy) data. 
We identified eligible individuals from a 20% random sample of Medicare beneficiaries with 
fee-for-service enrollment in all three plans for at least one month from October 19, 2010 
(when dabigatran was introduced) through December 31, 2012. New users were defined as 
individuals who initiated dabigatran or warfarin after a 1-year washout period with no 
prescription for any oral anti-coagulant.11 We required continuous enrollment in Medicare 
for at least 12 months prior to drug initiation. All demographic and clinical covariates 
(described below) were defined during the 12 months prior to drug initiation. Individuals 
were censored only if they lost Medicare enrollment during follow-up (intent-to-treat 
analysis).  
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We restricted our study cohort to individuals who were 65 years of age or older and 
had an inpatient or outpatient diagnosis code for atrial fibrillation or atrial flutter (ICD-9 
427.31, 427.32) prior to initiation of dabigatran or warfarin. We excluded individuals with a 
known heart valve replacement because this is a contraindication for dabigatran use. We 
also excluded individuals at a skilled nursing facility at drug initiation.  
Estimation of the DRS and PS. We modeled the one-year risk of combined ischemic 
stroke and all-cause mortality within a population of new warfarin users with an index date 
prior to the introduction of dabigatran (between January 1, 2008 and October 18, 2010). 
This model was then used to predict the disease risk for all individuals within the study 
cohort.  
We also estimated the PS within the study cohort for comparison. The PS and DRS models 
included main effects for the 37 covariates listed in Table 3.2, which were selected a priori 
using expert knowledge. We added 200 empirically selected covariates based on Medicare 
medication claims, inpatient and outpatient diagnostic codes, and procedural codes. We 
identified the 200 most prevalent codes within each data dimension (codes with a 
prevalence greater than 0.5 were subtracted from 1). Of the 600 covariates identified in this 
way, we selected the 200 with the strongest univariate associations (odds ratios) with the 
outcome. The estimated DRS and PS were implemented using 1-1 caliper matching with a 
caliper of 0.01 standard deviations of the respective DRS or PS distribution. We considered 
the dabigatran group to be the treated group. We estimated the hazard ratio within the 
matched populations using Cox proportional hazards models. 
We conducted analyses using 20 and 1 percent samples of the Medicare data to 
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observe the sensitivity of the results as the sample size is reduced. With smaller sample 
sizes, PS overfitting and the resulting separation in PS distributions across treatment groups 
will likely be more pronounced. Previous studies have shown that confounding can be 
stronger shortly after a treatment’s introduction.78-80 To observe the sensitivity of the 
results to the duration of follow-up, we repeated the analysis using data only for the first 
year of dabigatran use (index date between October 19, 2010 through October 18, 2011).  
3.6 Empirical Results 
 We present results for the empirical study in Figures 3.3 and 3.4 as well as Tables 3.2 
and 3.3. Table 3.2 shows the distribution of the 37 a priori selected covariates by treatment 
group. New users of dabigatran were generally healthier, with fewer comorbidities and 
greater use of the healthcare system than new users of warfarin (Table 3.2). Similar 
patterns of initiation have been found in other studies.81  
 Figures 3.3 and 3.4 show the PS and DRS distributions by treatment group for the 
20% (Figure 3.3) and 1% (Figure 3.4) samples of the Medicare data, with follow-up through 
2012. In both analyses, controlling for the larger set of empirically selected covariates 
resulted in greater separation in PS distributions while having little impact on the separation 
in DRS distributions. For the 20% sample (Table 3.3), approximately 100% of the treated 
population was matched on the PS and the DRS, regardless of the number of covariates 
included in the models. In this case, both PS and DRS matching resulted in similar hazard 
ratios and standard errors, both when controlling for the covariates selected a priori (HRs 
0.73 and 0.72 respectively; SEs both 0.03) and after adding the empirically selected 
covariates (HRs 0.88 and 0.87 respectively; SEs both 0.04). 
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When using the 1% sample of the Medicare data and controlling for the covariates 
selected a priori (Table 3.4), PS and DRS matching yielded similar results, with 
approximately 100% of the treated population being matched for both methods (HR and SE 
of 0.75 and 0.16 for PS matching and 0.75 and 0.15 for DRS matching). However, when 
controlling for the expanded covariate set in this sample, only 82% of the treated patients 
were matched on the PS, compared to approximately 100% on the DRS (Table 3.4). The 
reduction in the percentage matched resulted in reduced precision for the PS-matched 
estimate (SE 0.21 versus 0.18) (Table 3.3). In the analyses evaluating treatment effects in 
the first year of dabigatran use (not shown), the pattern of results was similar to that shown 
in Table 3.3, except that unadjusted and adjusted estimates were further from the null and 
standard errors were larger. 
Each of the PS models resulted in good model fit in terms of calibration and 
discrimination for all scenarios (Hosmer-Lemeshow p-value ranging from 0.52 to 0.65; c-
statistic ranging from 0.68 to 0.79). The PS models also performed well in terms of 
balancing covariates across treatment groups with an average standardized absolute mean 
difference (ASAMD) of 0.01 or less for all scenarios. In terms of predictive performance, the 
DRS models had good discrimination (c-statistic ranging from 0.73 to 0.78), but performed 
poorly in terms of calibration (Hosmer-Lemeshow p-value <0.01 for three out of four 
scenarios).   
3.7 Discussion 
In this study, we used both simulations and an empirical example to explore 
potential benefits of using a historically estimated DRS when controlling large numbers of 
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covariates in settings with newly introduced treatments. With few exposed individuals and 
smaller sample sizes, fitting a high-dimensional PS model can increase separation between 
the PS distributions of the treatment groups, reducing the number of treated individuals 
who can be matched on the PS. In theory, the overlap in DRS distributions should always be 
at least as great as the overlap in PS distributions across treatment groups. Therefore, 
matching on the DRS may allow researchers to evaluate the treatment effect within a larger 
proportion of the treated population, compared to matching on the PS. 
In the simulations, we demonstrated that when there was strong separation in the 
PS distributions across treatment groups, matching on the DRS can improve the precision of 
the effect estimate and, in the presence of treatment effect heterogeneity, provide more 
accurate estimates of the treatment effect in the full treated population. For the empirical 
example, we found that when there was moderate separation in the PS distributions across 
treatment groups, DRS and PS matching gave similar estimates of the effect of the new oral 
anticoagulant dabigatran versus warfarin in reducing combined ischemic stroke and all-
cause mortality within the Medicare population. However, when controlling for large 
numbers of covariates with reduced sample size, the separation in the PS distribution across 
treatment groups increased and matching on a historically estimated DRS improved the 
precision of the effect estimate by allowing a larger proportion of the treated population to 
be matched. For both PS and DRS matching, when we added a large set of empirically 
selected covariates, effect estimates became more consistent with the results of clinical 
trials and other studies comparing these treatments within the Medicare population.49, 82 
When we restricted the analysis to the first year of dabigatran use, estimates moved further 
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from the null (becoming less consistent with trial results), likely reflecting the strong 
channeling that occurs shortly after a treatment’s introduction.78-80  
While matching on the DRS can allow for a larger portion of individuals to be 
compared across treatment when there is separation in the PS distributions, it is important 
to consider why the PS distributions are separated. If the separation is due to strong 
differences in confounding variables rather than overfitting the PS model, researchers 
should proceed cautiously. Strong differences in measured confounders can indicate strong 
differences in unmeasured confounders, which could be addressed best in the study design 
phase rather than the analysis phase. We stress the importance of reducing differences in 
the distribution of baseline covariates across treatment groups through proper study design 
(e.g., new-user design and other restriction criteria).78, 83  
While we have focused on potential benefits of matching on the DRS, the DRS also 
has some theoretical disadvantages compared to the PS. Because the DRS is defined in 
terms of a potential outcome, estimating the DRS in practice can be challenging and 
requires additional assumptions. Further, unlike the PS, the DRS cannot be evaluated using 
measures of covariate balance within the full study population. In this study, the estimated 
PS models resulted in good model fit and PS matching balanced covariates across treatment 
groups. When modeling the DRS using historical data, we found it difficult to obtain good 
model fit in terms of the Hosmer-Lemeshow test, particularly when controlling for larger 
numbers of covariates. Other studies have reported similar findings when estimating high-
dimensional DRSs and have proposed implementing shrinkage methods to reduce the 
dimensionality of covariates to improve model fit.84 For this study, however, poor fit in 
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terms of the Hosmer-Lemeshow test did not appear to have a strong impact on the 
performance of the DRS compared with the PS. More research is needed to determine how 
best to estimate and evaluate the validity of DRS models. 
We conclude that under certain assumptions, using historical data to model the DRS 
is a valid method to control for confounding when evaluating newly marketed drugs. 
Further, when there is strong separation in the distribution of the PS across treatment 
groups, matching on a historically estimated DRS versus a PS can allow researchers to 
evaluate the treatment effect within a larger proportion of the treated population. We 
further conclude, however, that accurately modeling the DRS can be more challenging as 
compared to modeling the PS, even in settings involving newly introduced treatments. 
When using summary scores for confounding control, we recommend conducting and 
reporting results from PS analyses in addition to analyses using a historically estimated DRS. 
 
 
 
 
 
 
 
45 
 
3.8 Tables and Figures 
Table 3.1 Simulation results  
Scenarioa  Sample 
Size 
Method Bias St. 
Error 
MSE x10 % matched 
A       
 10,000      
  Unadjusted 0.06 0.08 0.11 ----- 
  PS match 0.01 0.09 0.08 98.8 
  DRS match 0.01 0.09 0.08 99.9 
 1,000      
  Unadjusted 0.06 0.23 0.56 ----- 
  PS match 0.00 0.27 0.72 89.2 
  DRS match 0.01 0.27 0.72 99.8 
B       
 10,000      
  Unadjusted 0.12 0.06 0.18 ----- 
  PS match 0.00 0.08 0.06 89.9 
  DRS match 0.01 0.07 0.06 99.9 
 1,000      
  Unadjusted 0.13 0.22 0.65 ----- 
  PS match 0.00 0.26 0.67 77.4 
  DRS match 0.00 0.22 0.48 99.9 
C        
 10,000      
  Unadjusted 0.23 0.05 0.55 ----- 
  PS match 0.00 0.06 0.04 58.9 
  DRS match 0.00 0.04 0.02 100 
 1,000      
  Unadjusted 0.23 0.16 0.79 ----- 
  PS match 0.01 0.25 0.63 47.7 
  DRS match 0.01 0.15 0.23 99.8 
D       
 10,000      
  Unadjusted 0.22 0.05 0.51 ----- 
  PS match 0.04 0.06 0.05 58.9 
  DRS match 0.01 0.04 0.02 100 
 1,000      
  Unadjusted 0.22 0.18 0.81 ----- 
  PS match 0.05 0.24 0.60 47.6 
  DRS match 0.01 0.16 0.26 99.9 
a Scenario A: mild covariate effects on treatment and outcome; Scenario B: moderate 
covariate effects on treatment and outome; Scenario C: strong covariate effects on treatment 
and outcome; Scenario D: treatment effect heterogeneity with strong covariate effects on 
treatment and outcome  
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Table 3.2 Baseline covariates measured during 1-year washout period 
 Warfarin 
(N=56,260) 
Dabigatran 150mg 
(N=11,407) 
Demographics:   
Age 78.91 76.76 
Race (1 white, 0 other) (%) 89.2 91.72 
Sex (% female) 42.17 48.95 
   
% Diagnoses   
Cardiovascular:   
      Chest pain 38.41 35.05 
      Heart disease 74.56 66.62 
      Heart failure 30.74 19.23 
      Hypertension 65.08 63.30 
      Hyperlipidemia 35.21 41.09 
      Myocardial Infarction 3.49 1.89 
      Cerebrovascular disease 21.29 17.38 
      Stroke   
           Ischemic 6.09 4.31 
           Hemorrhagic 0.34 0.16 
      TIA 6.9 6.34 
      VTE 10.36 1.67 
Diabetes 35.09 30.02 
Kidney disease 12.58 4.74 
Renal failure 16.09 5.75 
Bleeding 1.88 0.68 
Anemia 15.63 9.95 
   
Baseline Meds: (%)   
Anti-depressants 28.27 22.89 
Antihypertensives:   
      ACE/ARB 52.22 50.23 
      Loop diuretics 40.91 28.70 
      Nonloop diuretics  52.55 41.97 
Hypolipidemic drugs:   
      Statins  49.40 52.45 
      Fibrate 5.02 4.98 
Rate Control Therapy:   
      Beta blockers 70.83 71.99 
      CCB 43.97 41.80 
      Glycoside 18.49 17.10 
Rhythm Control Therapy 19.10 23.21 
   
Healthcare Use (average #):   
# ECG claims  3.74 3.80 
# PSA claims 0.36 0.49 
# of fecal occult blood tests 0.12 0.13 
# colonoscopies  0.14 0.14 
# flu shot claims 0.76 0.79 
# of lipid assessments 1.52 1.72 
# of mammography claims 0.25 0.29 
# of PapSmear claims 0.05 0.07 
 
 
Table 3.3 Empirical results comparing new users of dabigatran with new users of warfarin in preventing combined 
ischemic stroke and all-cause mortality in the Medicare population between October 19, 2010 and December 31, 2012.  
Sample Sizea # 
covsb 
Method Hazard 
Ratioc 
St. 
Errord 
95% CI % 
matched 
Model Fite 
c-stat p-value ASAMDf 
20% Sample          
  Unadjusted 0.48 0.02 (0.46, 0.50) ------ ------ ------ 0.14 
 37         
  PS match 0.73 0.03 (0.69, 0.77) 100 0.68 0.63 <0.01 
  DRS match 0.72 0.03 (0.68, 0.76) 100 0.73 <0.01 ------ 
 237         
  PS match 0.88 0.04 (0.81, 0.95) 100 0.73 0.52 <0.01 
  DRS match 0.87 0.04 (0.80, 0.94) 100 0.78 <0.01 ------ 
1% Sample          
  Unadjusted 0.47 0.07 (0.41, 0.54)    0.17 
 37         
  PS match 0.75 0.16 (0.55, 1.03) 98.3 0.71 0.65 0.01 
  DRS match 0.75 0.15 (0.56, 1.01) 100 0.73 0.18 ------ 
 237         
  PS match 0.89 0.21 (0.59, 1.34) 81.5 0.79 0.61 0.01 
  DRS match 0.86 0.18 (0.60, 1.22) 99.3 0.77 <0.01 ------ 
a 20% (N=67,667) and 1% (N=3,383) samples of the Medicare data. 
b Number of covariates in PS and DRS model 
c RELY trial relative risk for 150mg dabigatran vs warfarin:  0.76 (0.60, 0.98) for ischemic stroke;  0.88 (0.77, 1.00) for 
death from any cause. In the current study, >90% of the outcomes were death from any cause.  
d Bootstrapped standard errors. Hazard ratio estimates are the mean of the bootstrapped sampling distribution  
e c-statistic and p-value for each PS and DRS model. 
f The average standardized absolute difference (ASAMD) of covariates across PS matched treatment groups. Because 
the DRS does not balance covariates across treatment, the ASAMD was only calculated for PS models. The unadjusted 
ASAMD was calculated for all 237 covariates. 
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Figure 3.1 PS and DRS distributions across treatment groups with a sample size of 10,000 
subjects and 100 covariates included in the PS and DRS models. In plots A and B the effects 
of covariates on both treatment and the outcome were mild, in plots C and D covariate 
effects were moderate, and in plots E and F the covariate effects were strong. The 
overlapping coefficient is an estimate of the percentage of overlapping area between the 
two density functions. 
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Figure 3.2. PS and DRS distributions across treatment groups for one run of the simulation 
study with a sample size of 1,000 subjects and 100 covariates included in the PS and DRS 
models. In plots A and B the effects of covariates on both treatment and the outcome were 
mild, in plots C and D covariate effects were moderate, and in plots E and F the covariate 
effects were strong. The overlapping coefficient is an estimate of the percentage of 
overlapping area between the two density functions. 
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Figure 3.3.  PS and DRS distributions across dabigatran and warfarin treatment groups 
for a 10 percent sample of the Medicare dataand individuals with an index date 
between October 2010 and December 2012. In plots A and B the PS and DRS models 
included 37 a priori selected covariates. In plots C and D the PS and DRS models 
included 37 a priori selected covariates and 200 empirically selected covariates. The 
overlapping coefficient is an estimate of the percentage of overlapping area between 
the two density functions. 
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Figure 3.4.  PS and DRS distributions across dabigatran and warfarin treatment groups for a 
1 percent sample of the Medicare data and individuals with an index date between October 
2010 and December 2012. In plots A and B the PS and DRS models included 37 a priori 
selected covariates. In plots C and D the PS and DRS models included 37 a priori selected 
covariates and 200 empirically selected covariates. The overlapping coefficient is an 
estimate of the percentage of overlapping area between the two density functions.
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CHAPTER 4 
 
METRICS TO EVALUATE DISEASE RISK SCORES IN NON-EXPERIMENTAL RESEARCH 
 
4.1 Introduction 
 Controlling large numbers of confounding variables is a fundamental challenge in 
pharmacoepidemiologic research. Summary scores, which reduce baseline covariate 
information to a single dimension, have become increasingly popular for confounding 
adjustment. The propensity score, defined as the conditional probability of treatment given 
a set of measured covariates, has been the most widely used summary score for 
confounding control.2 An alternative to the propensity score is the prognostic score, also 
known as the disease risk score (DRS). Unlike the PS which models covariate associations 
with treatment assignment, the DRS models the associations between covariates with the 
outcome under the control or comparator treatment.5  
Both the PS and DRS control for measured confounders by acting as balancing 
scores. Rosenbaum & Rubin1 show that upon conditioning on the PS, measured covariates 
are independent of treatment assignment. Hansen5 shows that the DRS is also a balancing 
score, but instead of balancing covariates with respect to treatment assignment, the DRS 
acts as a “prognostic balancing” score in that conditioning on the DRS results in covariates 
being independent of the potential outcome under control (discussed further below).   
In practice, the PS and DRS are unknown and must be estimated from the available 
data. A favorable aspect of the PS is the ability to check the validity of the model by 
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assessing the balance of covariates across treatment groups within the entire study 
population. A number of studies have shown a strong correspondence between measures 
of covariate balance and the ability of the PS model to reduce confounding bias.85, 86 It has 
become common practice and recommended that PS estimation should be approached 
with the primary goal of minimizing covariate imbalance rather than focusing on the 
prediction of treatment assignment.34, 87, 88  
The optimal strategy for evaluating DRS models is less clear. The goal of the DRS is to 
control confounding by balancing covariates with respect to the potential outcome under 
control. Because this potential outcome is only observed for individuals receiving the 
comparator treatment, “prognostic balance” cannot be evaluated within the entire study 
population. Consequently, the validity of fitted DRS models has primarily been assessed 
through measures of predictive performance, including the c-statistic and goodness of fit 
tests. It remains unclear how well measures of predictive performance correspond with the 
ability of the DRS to reduce confounding bias. 
In this study we use simulations and an empirical example to compare metrics for 
evaluating the predictive performance of DRS models and their correspondence with bias in 
treatment effect estimates. We further discuss and evaluate a strategy proposed by 
Hansen73 where DRS models are evaluated in their ability to control confounding by 
performing a “dry run” analysis within a pseudo population of individuals who are sampled 
from the control population in a way to represent the covariate distributions within the full 
study cohort. Finally, we demonstrate the discussed concepts through an empirical example 
comparing dabigatran vs warfarin in preventing ischemic stroke and all-cause mortality 
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within the Medicare population. While a number of studies have discussed and analyzed 
ways for evaluating fitted PS models,85, 86 there remains little discussion in the literature 
regarding how DRS models should be evaluated when the goal of the DRS is to control for 
confounding bias. 
4.2 Background and Notation 
Following the Neyman-Rubin counterfactual framework,18, 19 let    represent the 
potential response had the individual received treatment and    the potential response had 
the individual received the control or comparator treatment. In practice, only one of the 
potential outcomes is observed. Let    represent the observed response and   a 
dichotomous treatment. Further, let   represent a set of measured baseline covariates with 
     the PS and     the DRS, both as a function of the baseline covariates  . 
Rosenbaum & Rubin1 show that upon conditioning on the PS, measured covariates 
are independent of treatment assignment. Formally expressed as          where  
denotes independence of random variables and | denotes conditional on, this 
independence results in covariates being balanced across treatment groups.  If treatment 
assignment is strongly ignorable, i.e.            , this property of covariate balance that 
results from conditioning on the propensity score satisfies                allowing for 
the identification of average treatment effects in the full population or within subgroups of 
the population (e.g., the treated population). If treatment assignment is weakly ignorable, 
i.e.       , then conditioning on the propensity score satisfies            allowing for 
the identification of the average treatment effects on the treated population. 
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Formally, a prognostic score is defined as any scalar or multi-dimensional function of 
  that satisfies the condition          .
5 In other words, conditioning on the DRS results 
in a form of covariate balance where the potential response under the comparator 
treatment is independent of a set of measured covariates,  . Hansen5 shows that if 
treatment assignment is weakly ignorable, then conditioning on the DRS satisfies 
          allowing for unconfounded estimates of treatment effects in the treated 
population through stratification or matching.  
If the outcome follows a generalized linear model, then one possible DRS is the 
linear predictor of   , or the conditional mean of    given   (i.e.,        ). In practice,    is 
only observed for individuals receiving the comparator treatment and the function         
must be estimated indirectly for the treated population.   
4.2.1 Challenges when modeling the DRS and evaluating its ability to control confounding 
The DRS has primarily been estimated in one of two ways: 1) model          within 
the cohort of individuals receiving the comparator treatment and then extrapolate this 
model to predict disease risk for all individuals within the full cohort; 2) model the function 
          by fitting a regression model to the full cohort (i.e., both treated and control) as 
a function of baseline covariates and treatment, and then estimate         for each 
individual through the function            by setting treatment status to zero.6, 7, 23, 30, 31 
Fitting the DRS to the full cohort benefits from increased sample size, but requires 
accurately modeling the relationship between the treatment and outcome. Small 
misspecifications in the full cohort DRS model can result in the estimated scores that carry 
information about the treatment effect. This non-ancillarity in the estimated DRSs can 
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introduce bias when used for confounding control.5, 30 Consequently, Hansen5 recommends 
using only the control population when fitting the DRS model to ensure partial ancillarity in 
the estimated scores. Leacy30 explains that using only the control population when 
modeling the DRS tends to result in estimated scores that are more robust to model 
misspecification. Fitting the DRS only within individuals receiving the comparator treatment, 
however, increases the potential for overfitting the risk model to the control population in 
the study cohort. Such overfitting can overestimate disease risk for high-risk comparator 
patients and underestimating disease risk for low-risk comparator patients, leading to 
apparent treatment effect heterogeneity over the distribution of disease risk and 
potentially biased effect estimates.3, 5, 32  
Both Hansen5 and Glynn3 have proposed that fitting the DRS within a historical 
sample of controls can reduce problems of overfitting. This strategy has received particular 
attention in pharmacoepidemiologic studies involving large automated databases and the 
evaluation of newly introduced treatments.3, 32 Fitting the DRS within historical controls, 
however, requires additional assumptions that the effects of risk factors on the outcome, 
coding practices, and surveillance of individuals do not change over time. These difficulties 
when modeling the DRS highlight the importance of evaluating the validity of fitted DRS 
models.  
If measures of prognostic balance were available within the full study population, 
these measures could be used to evaluate DRS models in a similar way that measures of 
covariate balance across treatment groups are used to evaluate PS models. However, 
prognostic balance can only be evaluated within individuals receiving the comparator 
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treatment. Measuring prognostic balance only within the comparator group can potentially 
reward models that are overfit to the control population. Further, in the presence of 
unmeasured confounding, the DRS does not result in prognostic balance within subgroups 
of treatment, but only marginally within the entire population.5, 32 Fitted risk models that 
induce prognostic balance within the control population does not imply that those models 
will induce prognostic balance within the entire study cohort. 
4.3 Dry Run Analysis 
Hansen73 proposes incorporating the propensity score when evaluating the ability of 
risk scores to control confounding. Hansen explains that, in theory, researchers can use the 
propensity score to draw weighted samples from the control population to create “pseudo 
treatment” and “pseudo control” groups whose covariate distributions on measured 
covariates are representative of the treated and control populations in the full study 
cohort.73  With no treatment effect separating the pseudo treated and pseudo control 
groups, researchers can perform a “dry run” analysis by fitting the DRS model to the pseudo 
control group, or a historical set of controls, and then evaluate the validity of the fitted 
model based on its ability to control for confounding within the pseudo population. If 
subclassification or matching on the estimated DRSs result in unconfounded null effect 
estimates within the pseudo population, then the fitted model should be successful in 
controlling confounding on the same measured covariates within the original sample.  
To create a “pseudo treatment” group, individuals are sampled from the control 
population within the study cohort with weights proportional to the odds of receiving 
treatment. For the “pseudo control” group, individuals are sampled with weights of one. 
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Sampling can be done with or without replacement. Sampling with replacement is similar in 
concept to standardized mortality ratio (SMR) weighting where a portion of the control 
population is weighted to represent the PS distribution within the treated population.89 
With smaller sample sizes or large weights, sampling with replacement can result in the 
same individuals being sampled many times over. Sampling without replacement avoids this 
problem, but requires a more complicated sampling scheme known as maximum entropy 
sampling to maximize information when sampling from a finite population. Chen et al.74 
provide a detailed explanation of maximum entropy sampling from finite samples.  
In theory, this strategy provides a more direct approach for evaluating the ability of 
a DRS model to control for measured confounding. There remains little evidence, however, 
of its performance in practice and the optimal strategy for evaluating DRS models remains 
unclear.  
4.4 Simulation Study 
We simulated a dichotomous treatment ( ) and outcome ( ), six binary covariates 
(                  ) and four standard-normal covariates (           ). We defined the 
conditional probability of treatment and outcome according to Equations 4.1 and 4.2.  
                                                                                                          
                               
        
                    [4.1] 
                                                                                                     
                               
        
             [4.2] 
The coefficient values for    and   ,   1,…,10, were selected by drawing values 
from separate uniform(-.7,.7) distributions. This range of values (i.e., potentially ranging 
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from -0.7 to 0.7) was chosen to reflect the range for the majority of coefficient values 
observed in an empirical example comparing dabigatran versus warfarin described below. 
We repeated this process 50 times by drawing a separate set of values for    and   , 
  1,…,10, to consider a total of 50 unique parameter combinations. With each parameter 
combination we simulated 100 datasets and fit 32 unique DRS models using logistic 
regression with various degrees of model misspecification. Each of the models included 
main effects for the covariates    through    , but different sets of higher order terms. We 
considered all possible combinations of the higher order terms (32 total). We fit the DRS 
models within a simulated historical set of data that was similar to the study cohort, but 
with no treatment introduced.  
We evaluated the predictive performance for each DRS model within the original 
study cohort by calculating three measures of predictive performance: the c-statistic, the 
Hosmer-Lemeshow goodness of fit test and the mean squared error (MSE) of the predicted 
values. We also evaluated each DRS model by performing a “dry run” analysis to calculate 
the pseudo bias after stratifying on the fitted DRSs within a pseudo population. We created 
pseudo treatment and control groups by sampling with replacement from the actual control 
population in the original study cohort with weights proportional to the odds of the PS or 
one respectively. Because the dry run analysis relies on using the PS to create the sampling 
weights, we estimated the PS using logistic regression and considered different degrees of 
misspecification: no misspecification (included all higher order terms), moderate 
misspecification (excluded one quadratic and one interaction term), and strong 
misspecification (excluded all higher order terms).  Finally, we evaluated the correlation 
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between bias in the effect estimates with the measures of predictive performance and the 
calculated pseudo bias.  
For each parameter combination, we repeated the analysis to consider scenarios 
involving smaller sample sizes, low prevalence of both treatment and outcome, risk factors 
(i.e., variables that affect the outcome but have no effect on treatment), different 
distributions for baseline covariates, and different directions in confounding. We also 
repeated all analyses using a probit model to simulate treatment and the outcome (i.e., 
probit rather than logit model in Equations 1 and 2). Simulating data with a probit model 
allowed us to evaluate scenarios where model misspecification in the PS and DRS models 
was a result of the functional form of covariates in the model as well as the functional form 
of the model itself (i.e., misspecified link function). In this case, there was mild 
misspecification in both the fitted PS and DRS models even when all higher order terms 
were included within the models. Table 4.1 provides a description of the simulated 
scenarios. 
4.5 Simulation Results 
We present results for the simulation study in Figures 4.1 and 4.2, and Table 4.2. 
Figures 4.1a through 4.1f show box plots for the Spearman correlation coefficients between 
each of the described measures for evaluating DRS models and the absolute bias in the 
treatment effect. Each box-plot shows the distribution of 50 correlation coefficients (one 
correlation coefficient for each of the 50 parameter combinations). Each sub figure 
represents a different simulation scenario.  
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When the PS was correctly specified, there was a very strong correlation between 
the calculated pseudo bias and the actual bias within the original study cohort (Figure 4.1a). 
As the misspecification in the PS model increased, the strength of this correlation became 
less pronounced (Figures 4.1c and 4.1e). The correlation between the measures of 
predictive performance and bias were less consistent and attenuated compared to the 
correlation between the full cohort study bias and the pseudo bias when the PS was 
correctly specified (Figures 4.1a-4.1f).  Among the measures of predictive performance, the 
p-value for the Hosmer-Lemeshow goodness-of-fit test showed the weakest correlation 
with predicting bias in the effect estimate (Figure 4.1d). Similar patterns were found when 
treatment and outcome were simulated using a probit model (results not shown). In this 
case, pseudo bias1 represented the bias within the pseudo population when there was mild 
misspecification in the PS model.  
Figure 4.1 shows that the c-statistic and MSE had good performance in predicting 
bias in the effect estimate when comparing various models fit to the same dataset. In 
practice, however, researchers will often want to make a decision on a single fitted model 
to decide if the model is appropriate. The calculated pseudo bias and p-value from 
goodness-of-fit tests may have an advantage in this case as the actual values from these 
measures can carry the same meaning across different data generating models (e.g., a p-
value of <0.01 implies poor model fit regardless of the data generating model). To explore 
this issue, we calculated a single correlation for each measure after combining the 
calculated values across all parameter combinations and scenarios instead of calculating the 
correlation between each measure and bias separately for each data generating model 
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(Figure 4.2). Similar to Figure 4.1, when the PS was correctly specified, the calculated 
pseudo bias showed the strongest correlation with bias in the treatment effect and had a 
calculated intercept from the least squares regression line of approximately 0 (Figure 4.2a). 
Among the measures of predictive performance, the p-value from the Hosmer-Lemeshow 
test showed the strongest correlation after combining results across different data 
generating models (Figure 4.2d).  
4.6 Empirical Example: Dabigatran vs Warfarin  
We compared the performance of dabigatran vs warfarin in an elderly population 
using a 20 percent sample of linked Medicare parts A (hospital), B (outpatient), and D 
(pharmacy) data. We included Medicare beneficiaries with fee for service enrollment in all 
three plans for at least one month between October 19, 2010 through December 31, 2012. 
New users were defined as individuals who initiated dabigatran or warfarin after a 1 year 
washout period of having no prescription for either dabigatran, warfarin, or any other oral 
anti-coagulant. We included all individuals who were continuously enrolled in Medicare for 
at least 12 months prior to drug initiation. All demographic and clinical covariates were 
defined during the 12 months prior to drug initiation. Individuals were censored only if they 
lost enrollment in the Medicare system during follow-up (intent to treat analysis).  
We restricted our study cohort to individuals who were 65 years of age or older and 
had an inpatient or outpatient diagnosis code for atrial fibrillation or atrial flutter (ICD-9 
427.31, 427.32) prior to initiation of dabigatran or warfarin. We excluded individuals with a 
known heart valve transplant since this is a contraindication for dabigatran use. We also 
excluded individuals at a skilled nursing facility at drug initiation since diagnoses within 
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these facilities are not always captured within Medicare claims data.  
To avoid overfitting the risk model to the control population within the study cohort, 
we modeled the one year risk of combined ischemic stroke and all-cause mortality within a 
historical population of new warfarin users with an index date prior to the introduction of 
dabigatran (between January 1, 2008 through October 18, 2010). This model was then used 
to predict the disease risk for all individuals within the study cohort. We fit PS and DRS 
models that included main effects for each of the covariates listed in Table 4.2 and an 
additional 200 empirically selected covariates that were identified within Medicare files 
containing medication claims, inpatient and outpatient diagnostic codes and procedural 
codes. When selecting the 200 empirically selected covariates, we first identified the top 
200 most prevalent codes within each data dimension (codes with a prevalence greater 
than 0.5 were subtracted from 1). We then selected the top 200 codes based on the 
strength of their univariate association (odds ratio) with the outcome. The estimated DRSs 
were implemented through stratification and again through 5-1 digit matching.90  
To evaluate the validity of the fitted DRS model, we created a pseudo treatment 
group by sampling new-warfarin users within the original study cohort (i.e., index date after 
October 19, 2010). Sampling was done with replacement and with weights proportional to 
the odds of the PS. We created a pseudo control group by sampling with replacement from 
the same population, but with weights equal to one. We then evaluated the validity of the 
historically fitted DRS model by observing how well stratifying on the estimated scores 
controlled for confounding within the pseudo population. For comparison, we also 
evaluated the predictive performance of the estimated DRSs by assessing the calibration 
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(Hosmer-Lemeshow goodness of fit test) and discrimination (c-statistic) of the predicted 
values.  
4.7 Empirical Results 
We present results for the empirical study in Figure 4.3 and Tables 4.2 and 4.3.  
Table 4.2 shows the distribution of 37 a priori selected covariates across treatment groups. 
New-users of dabigatran were generally healthier with fewer comorbidities and greater use 
of the healthcare system than new-users of warfarin (Table 4.2). Similar patterns of 
initiation have been found in other studies.81 Figure 4.3 shows similar PS distributions 
between the sampled pseudo population and original study cohort. Assuming the PS model 
is a close approximation to the true PS function, then the distribution of measured 
covariates across treatment groups and degree of confounding should also be similar across 
the pseudo and original study cohorts. 
In Table 4.3 we present the unadjusted hazard ratio, as well as hazard ratios after 
DRS and PS matching. In Table 4.3 we also present measures for evaluating the validity of 
the historically estimated DRS as well as the PS model. Both PS and DRS matching resulted 
in similar effect estimates with hazard ratios of 0.88 (0.81, 0.95)and 0.87 (0.80, 0.94) 
respectively. The fitted PS model resulted in good predictive performance in terms of 
discrimination and calibration with a c-statistic of 0.73 and hosmer-lemeshow p-value of 
0.52 (Table 4.3). The fitted DRS also resulted in good discrimination with a c-statistic of 0.78, 
but poor calibration in terms of the hosmer-lemeshow goodness-of-fit test with a p-value of 
<0.01 (Table 4.3). After matching on the PS, treatment groups were approximately balanced 
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on measured covariates with an ASAMD of <0.01, while DRS matching resulted in a pseudo 
bias of approximately 0.01 (Table 4).  
4.8 Discussion 
 In this study, we used simulations and an empirical example to compare various 
measures for evaluating DRS models in their ability to reduce bias in effect estimates.  We 
considered three measures of predictive performance including the c-statistic, the p-value 
from the Hosmer-Lemeshow goodness of fit test, and the MSE of the predicted values. We 
also evaluated the performance of the “dry run” method proposed by Hansen73 where the 
fitted DRS is evaluated within a “pseudo population” of individuals who are sampled from 
the control population to create pseudo treatment and pseudo control groups that are 
representative of the original study cohort.  In simulations, the calculated pseudo bias from 
the “dry run” had the strongest correlation with the bias in the treatment effect estimate 
when the functional form of the PS was either correctly specified or a close approximation 
to the true PS model. When there was moderate to strong misspecification in the PS, there 
was little to no correlation between the calculated pseudo bias from the dry run with the 
bias in the effect estimate.  
Among the measures that evaluated the predictive performance of the fitted DRS 
models, the c-statistic and mse had the strongest correlation with bias in the effect estimate 
when comparing various models fit to the same data. In practice, however, researchers will 
often fit a single model (e.g., high-dimensional PS or DRS) and want to make a decision if 
the model is adequate in terms of confounding control. The c-statistic and MSE do not 
provide the best information for researchers when making a decision on a single DRS 
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model. In this study, we found that the c-statistic and MSE showed little to no correlation 
with bias in the effect estimate after combining measures across various data generating 
models.  
Overall, we found that measures for evaluating the predictive performance of DRS 
models did not always correspond well with reduced bias in the estimated treatment effect. 
Previous studies have reported similar findings when evaluating PS models.33, 34, 91  To what 
extent measures of predictive performance should be used when evaluating summary 
scores remains uncertain. Measures of predictive performance do not directly evaluate the 
ability of summary scores to control confounding. In contrast, measures of covariate 
balance across treatment groups when fitting the PS and the calculated pseudo bias within 
a “dry run” analysis when fitting the DRS can provide more direct measures for assessing 
the ability of the fitted models to control confounding.  
Creating a pseudo population that is representative of the original study cohort 
requires accurate estimation of the PS. In this case, one could simply use the PS for 
confounding control. The DRS, however, has some desirable qualities that can be beneficial 
to researchers even when a correctly specified PS is available. DRSs provide a natural 
measure to evaluate treatment effect heterogeneity. When making treatment decisions, 
clinicians are almost always concerned about how the effect of a treatment varies over 
various patient profiles affecting the risk for the outcome (e.g., 10 year risk for 
cardiovascular disease based on the Framingham risk score).  Although the PS allows us to 
detect and account for treatment effect heterogeneity, it does not provide the best 
information for health care providers in determining what subgroups of the patient 
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population are most likely to benefit from a given treatment regime. Further, matching or 
stratifying on the PS can be more restrictive then matching or stratifying on the DRS. The 
DRS can potentially allow for a greater number of individuals to be compared across 
treatment groups than the PS. This can be beneficial when there is strong separation in PS 
distributions (e.g., strong channeling with newly introduced treatments). 
As with any simulation and empirical example, results are limited to the scenarios 
assessed. More research is needed to evaluate the performance of the discussed methods 
over a wide range of settings specific to large database research. Further, the optimal 
strategy for sampling from the control population when performing a “dry run” analysis 
remains unclear. More research is needed to evaluate various sampling strategies when 
creating pseudo treatment and pseudo control groups. Finally, neither measures of 
covariate balance for the PS or a “dry run” analysis for the DRS provide information on bias 
caused by unmeasured confounding or proper variable selection. We therefore stress the 
importance of using subject matter expertise to gain an understanding of the underlying 
causal structure before performing PS or DRS analyses.83 
We conclude that accurately modeling the DRS within the study cohort, or within a 
historical set of controls presents unique challenges that are not shared by the PS. 
Measures of predictive performance do not necessarily identify the ability of a DRS model 
to control confounding.  If the PS can be accurately modeled, evaluating the ability of the 
DRS model to control confounding within a “dry run” analysis can provide insight into the 
validity of fitted DRS models. 
 
 
 
4.9 Tables and Figures 
Table 4.1. Simulation Scenarios 
Scenario Distribution of Covs Direction of 
Confounding 
Baseline Prev 
of T and Y 
Type of covariates Sample 
size (n) 
 Binomial(0.5) Normal(0,1)   Confounder Risk factor  
A                                Both directions 50%        ----- 10,000 
B                                Both directions 10%        ----- 10,000 
C -------        Both directions 50%        ----- 10,000 
D                                Both directions 50%        ----- 1,000 
E                                Both directions 50%              10,000 
F                                Same direction 50%        ----- 10,000 
 
 
6
8
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Table 4.2: Baseline covariates during 1 year washout period 
 Warfarin 
(N=56,260) 
Dabigatran 150mg 
(N=11,407) 
Demographics:   
Age 78.91 76.76 
Race (1 white, 0 other) (%) 89.2 91.72 
Sex (% female) 42.17 48.95 
   
% Diagnoses   
Cardiovascular:   
      Chest pain 38.41 35.05 
      Heart disease 74.56 66.62 
      Heart failure 30.74 19.23 
      Hypertension 65.08 63.30 
      Hyperlipidemia 35.21 41.09 
      Myocardial Infarction 3.49 1.89 
      Cerebrovascular disease 21.29 17.38 
      Stroke   
           Ischemic 6.09 4.31 
           Hemorrhagic 0.34 0.16 
      TIA 6.9 6.34 
      VTE 10.36 1.67 
Diabetes 35.09 30.02 
Kidney disease 12.58 4.74 
Renal failure 16.09 5.75 
Bleeding 1.88 0.68 
Anemia 15.63 9.95 
   
Baseline Meds: (%)   
Anti-depressants 28.27 22.89 
Antihypertensives:   
      ACE/ARB 52.22 50.23 
      Loop diuretics 40.91 28.70 
      Nonloop diuretics  52.55 41.97 
Hypolipidemic drugs:   
      Statins  49.40 52.45 
      Fibrate 5.02 4.98 
Rate Control Therapy:   
      Beta blockers 70.83 71.99 
      CCB 43.97 41.80 
      Glycoside 18.49 17.10 
Rhythm Control Therapy 19.10 23.21 
   
Healthcare Use (average #):   
# ECG claims  3.74 3.80 
# PSA claims 0.36 0.49 
# of fecal occult blood tests 0.12 0.13 
# colonoscopies  0.14 0.14 
# flu shot claims 0.76 0.79 
# of lipid assessments 1.52 1.72 
# of mammography claims 0.25 0.29 
# of PapSmear claims 0.05 0.07 
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Table 4.3. Empirical results comparing dabigatran vs warfarin in the Medicare population between 
October 19, 2010 through December 31, 2013 (n=67,667)  
# covsa Method HR (95% CI) Pseudo 
biasa 
ASAMDb c-
statistic 
Hosmer 
lemeshow testc 
237       
 Unadjusted 0.48 (0.46, 0.50) 0.45 0.12 ----- ----- 
 PS matching 0.88 (0.81, 0.95) ----- 0.01 0.73 p=0.52 
 DRS matching 0.87 (0.80, 0.94) 0.01 ----- 0.78 p<0.01 
a PS and DRS models included 200 empirically selected covariates and 37 covariates selected a priori. 
b average standardized absolute mean difference of covariates across treatment groups 
c p-value from Hosmer-Lemeshow goodness of fit test 
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Figure 4.1. Box-plots of the correlation coefficients between each measure and absolute bias in the 
effect estimate for all parameter combinations. Each box-plot contains the correlation coefficients 
for the given measure across all parameter combinations. Plot a) shows  the box plots for the basic 
scenario; plot b) the scenario containing low treatment and outcome prevalence, plot c) the 
scenario containing all continuous variables; plot d) small sample size; plot e) both confounders and 
risk factors in DRS; and plot f) confounding only in one direction. 
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Figure 4.2. Measures for evaluating DRS models plotted against the absolute bias in the effect 
estimate for all parameter combinations in the basic scenario. Pseudo bias 1 in plot a) is the 
absolute bias within the pseudo population when the PS is mildly misspecified.  Pseudo bias 2 in plot 
c) represents the bias in the pseudo population when the PS model is moderately misspecified, and 
pseudo bias 3 in plot e) when the PS model is strongly misspecified.  
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Figure 4.3. Propensity score distributions from original study cohort of dabigatran and warfarin new-
users plotted against the pseudo propensity score distributions from the pseudo population of 
warfarin new-users. 
74 
 
CHAPTER 5 
CONCLUSIONS & PUBLIC HEALTH SIGNIFICANCE 
5.1 Summary of Specific Aims 
 Health care providers need rapid evaluation of newly marketed drugs to make 
timely decisions and optimize patient care. Large head-to-head clinical trials remain the 
gold standard when evaluating the efficacy of a given treatment, but can have limited 
generalizability and require long periods of time to complete. Electronic health care 
databases can provide timely information on patient populations who take newly 
introduced treatments in real time. Analyzing these data, however, present methodological 
challenges. Strong channeling and selective prescribing can lead to confounding by 
indication, requiring statistical methods and appropriate study design when evaluating 
these data.  
Propensity scores have become widely used for controlling large numbers of 
confounding variables in large database research. It has been hypothesized, however, that 
the performance of PS methods may be limited when evaluating newly introduced 
treatments. A historically estimated disease risk score has been proposed as an alternative 
method for controlling large numbers of covariates in these settings. However, accurately 
modeling the disease risk score presents many challenges and it remains unclear if the use 
of disease risk scores in these settings is advantageous.
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5.1.1 Summary of Aim 1 
Using Medicare data, we examined the performance of using a historically estimated 
disease risk score when evaluating the comparative effectiveness of newly marketed drugs. 
We focused on evaluating the comparative effectiveness of the new oral-anticoagulant 
dabigatran with warfarin in preventing combined ischemic stroke and all-cause mortality. 
Currently, there is limited information available on the net beneficial gains that new oral 
anticoagulant medications have on cardiovascular events compared to warfarin in real-
world practice.   
Due to the very recent approval of these new oral anticoagulants, their evaluation in 
non-experimental settings is difficult, in part due to the limited data available to control for 
large sets of confounders. It has been hypothesized that out-of-sample estimation methods 
for disease risk can be advantageous because these methods will allow for the control of a 
large number of risk factors at the start of drug introduction, potentially allowing 
researchers to evaluate the comparative effectiveness of these newer medications at earlier 
periods than previous methods.  
When comparing dabigatran with warfarin, we found that dabigatran new-users 
tended to be younger and healthier than new-users of warfarin. After controlling for a high-
dimensional set of covariates, effect estimates were more consistent with clinical trials. 
Controlling for a high-dimensional set of baseline covariates can improve confounding 
control, but can also create separation in the PS distributions across treatment groups, 
limiting the number of exchangeable individuals within the study cohort. When PS 
distributions are separated, we found that the DRS can allow researchers to compare the 
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treatment effect within a larger proportion of the population, potentially improving 
precision and the accuracy of the treatment effect when the parameter of interest is the 
average treatment effect in the full treated population. In this study, we found that this 
benefit of the DRS is most pronounced with smaller sample sizes. Finally, while it has been 
hypothesized that the DRS can be more stable over time potentially simplifying its 
estimation compared to the PS for newly marketed drugs, in our example we found 
modeling the DRS to be more challenging than modelling the PS. In general, modeling the 
DRS presents more challenges than modelling the PS, even in settings involving new 
treatments. Reporting results from PS analyses in addition to analyses using a historically 
estimated DRS can be beneficial in comparative effectiveness research of new treatments. 
5.1.2 Summary of Aim 2 
Accurately modeling the DRS, either within historical set of controls or the original 
study cohort, presents challenges that are not shared when modeling the PS. These 
difficulties highlight the importance of evaluating the validity of fitted DRS models.   
Researchers have primarily evaluated risk models by assessing their predictive performance 
in terms of discrimination (e.g., c-statistic) and calibration (e.g., goodness of fit tests). In this 
study, we found that measures for evaluating the predictive performance of DRS models did 
not always correspond well with reduced bias in the estimated treatment effect. In 
contrast, measures of covariate balance across treatment groups when fitting the PS and 
the calculated pseudo bias within a “dry run” analysis when fitting the DRS can provide 
more direct measures for assessing the ability of summary scores to control confounding.  
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Creating a pseudo population that is representative of the original study cohort 
requires accurate estimation of the PS. In this case, one could simply use the PS for 
confounding control. The DRS, however, has some desirable qualities that can be beneficial 
to researchers even when a correctly specified PS is available. DRSs provide a natural 
measure to evaluate treatment effect heterogeneity and can allow for a greater number of 
individuals to be compared across treatment groups than the PS. This can be beneficial 
when there is strong separation in PS distributions (e.g., strong channeling with newly 
introduced treatments). In conclusion, the DRS can be beneficial when evaluating newly 
introduced treatments. Finding more accurate ways to evaluate the validity of fitted DRS 
models can improve the quality of the estimation of disease risk scores. Hansen’s proposed 
method of evaluating the fitted DRS within a “dry run” analysis is promising, but more 
research is needed over a range of settings specific to large database research. 
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